Aprea Therapeutics (APRE.Q) today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. “The…
Stem cells
Creative Medical Technology Holdings (CELZ.OTC) announced proof of concept studies to demonstrate the efficacy and use-value of their ImmCelz immunotherapy product for the treatment of rheumatoid arthritis today. Rheumatoid…
It is well understood by now–academically in some cases, painfully in others–that an LP’s problems do not increase on a linear scale. As a facility doubles its size and…